X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CPI-613 (devimistat), is a selective mitochondrial metabolism inhibitor which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.
Lead Product(s): Devimistat,Gemcitabine
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
CPI-613® (devimistat) is a first-in-class clinical lead compound of Cornerstone, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.
Lead Product(s): Devimistat,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Wisconsin Medical Cyclotron & Radiopharmacy
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
CPI-613® (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth.
Lead Product(s): Devimistat,Oxaliplatin,Levoleucovorin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
Sudy published in PLOS ONE titled, Evidence for novel, effective approach to targeting carcinoma catabolism exploiting anti-cancer mitochondrial drug, CPI-613 multi-target, tumor-preferential inhibition of mitochondrial TCA cycle by first-in-class drug, devimistat.
Lead Product(s): Devimistat,Oxaliplatin,Levoleucovorin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
Details:
CPI-613® (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth.
Lead Product(s): Devimistat,Oxaliplatin,Levoleucovorin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
CPI-613® (devimistat) is a first-in-class clinical lead compound of Cornerstone, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.
Lead Product(s): Devimistat,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
Rafael Pharmaceuticals' lead compound devimistat (CPI-613®) is designed to selectively target the tumor mitochondrial tricarboxylic acid (TCA) cycle, a process essential to tumor cell multiplication and survival.
Lead Product(s): Devimistat,Cytarabine,Mitoxantrone
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2021
Details:
CPI-613® (devimistat) is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.
Lead Product(s): Devimistat,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2021
Details:
CPI-613® (devimistat) is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.
Lead Product(s): Devimistat,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
CPI-613® (devimistat) is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.
Lead Product(s): Devimistat,Oxaliplatin,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2021
Details:
The multicenter, open-label, randomized pivotal trial is assessing the efficacy and safety of Rafael’s lead compound CPI-613® (devimistat) in combination with high dose cytarabine and mitoxantrone compared to high dose cytarabine and mitoxantrone therapy in older patients.
Lead Product(s): Devimistat,Cytarabine,Mitoxantrone
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
This announcement comes on the heels of the Company receiving Fast Track designation for devimistat for the treatment of metastatic pancreatic cancer, in November. FDA has granted Fast Track designation for the Company’s lead compound, CPI-613®, for the treatment of AML.
Lead Product(s): Devimistat,Cytarabine,Mitoxantrone
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
Rafael Pharmaceuticals will initiate a Phase 2 clinical trial of CPI-613®(devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue, in partnership with Sara’s Cure and Sarcoma Alliance for Research through Collaboration (SARC).
Lead Product(s): Devimistat,Hydroxychloroquine Sulphate
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sara’s Cure
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 01, 2020
Details:
CPI-613® (devimistat) is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.
Lead Product(s): Devimistat,Oxaliplatin,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
Devimistat is designed to target the mitochondrial tricarboxylic acid cycle, a process essential to tumor cell multiplication and survival, selectively in cancer cells and substantially increases the sensitivity of cancer cells to a diverse range of chemotherapeutic agents.
Lead Product(s): Devimistat,Hydroxychloroquine Sulphate
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
The multicenter, open-label, randomized pivotal trial is assessing the efficacy and safety of Rafael’s lead compound CPI-613® (devimistat) in combination with high dose cytarabine and mitoxantrone compared to high dose cytarabine and mitoxantrone therapy in older patients.
Lead Product(s): Devimistat,Cytarabine,Mitoxantrone
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
CPI-613® (devimistat) is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells.
Lead Product(s): Devimistat,Oxaliplatin,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
Rafael has reached its target enrollment of 500 patients in its pivotal Phase 3 trial for metastatic pancreatic cancer (AVENGER 500), which is evaluating the efficacy and safety of CPI-613®️ (devimistat) in combination with modified FOLFIRINOX (mFFX) as first-line therapy.
Lead Product(s): Devimistat,Oxaliplatin,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
The multicenter, open-label, randomized pivotal trial is evaluating the efficacy and safety of its lead compound devimistat in combination with high dose cytarabine and mitoxantrone (CHAM) in older patients.
Lead Product(s): Devimistat,Cytarabine,Mitoxantrone
Therapeutic Area: Oncology Product Name: CPI-613
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
The collaboration aims at evaluating the efficacy of CPI-613® (devimistat) in combination with chemotherapy agents azacitidine and venetoclax on acute myeloid leukemia (AML) models.
Lead Product(s): Devimistat,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 07, 2020
Details:
ARMADA 2000 will be evaluating the efficacy and safety of Rafael’s CPI-613® in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone.
Lead Product(s): Devimistat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
Phase 3 trial for metastatic pancreatic cancer (AVENGER 500) is evaluating the efficacy and safety of Rafael’s lead compound CPI-613®? with modified FOLFIRINOX (mFFX) as first-line therapy.
Lead Product(s): Devimistat,Oxaliplatin,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2020
Details:
The Phase 1b/2 Clinical Trial of CPI-613® will identify the maximum tolerated dose of devimistat that does not cause side effects, when given in combination with gemcitabine and cisplatin.
Lead Product(s): Devimistat,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2020
Details:
Clinical trial using devimistat in combination with FOLFIRINOX as first-line treatment has enrolled more than 250 patients ahead of scheduled timeline.
Lead Product(s): Devimistat,Oxaliplatin,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
